These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6739373)

  • 41. [Pharmacology and metabolism of a new therapeutic drug for prostatic cancer "Estracyt"].
    Yamanaka H; Shida K
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):537-44. PubMed ID: 6422861
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Complete androgen blockade (orchiectomy + flutamide) versus androgen blockade with cytostasis (orchiectomy + estramustine) in the treatment of virginal advanced prostate cancer].
    Flamm J; Fischer M
    Wien Klin Wochenschr; 1988 Sep; 100(17):589-92. PubMed ID: 3055689
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Treatment of advanced metastasizing carcinoma of the prostate with estracyt (author's transl)].
    Rambausek M; Lutherer S; Terhorst B
    Urologe A; 1981 Jul; 20(4):223-7. PubMed ID: 7196632
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Total remission of prostatic cancer following treatment with Estracyt].
    Romics I
    Orv Hetil; 1982 Jan; 123(5):287-9. PubMed ID: 7063244
    [No Abstract]   [Full Text] [Related]  

  • 45. Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7.
    Fosså SD; Wiklund F; Klepp O; Angelsen A; Solberg A; Damber JE; Hoyer M; Widmark A;
    Eur Urol; 2016 Oct; 70(4):684-691. PubMed ID: 27025586
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Stage D1 prostatic cancer benefited by a single regimen of Estracyt].
    Hata M
    Gan To Kagaku Ryoho; 1988 May; 15(5):1787-90. PubMed ID: 3369873
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Cellular immunity in prostatic cancer modified by Cytonal, Estrazyt and Turisteron].
    Klebingat KJ; Panzig E; Lorenz G; Steinhauser I; Fiedler R
    Z Urol Nephrol; 1987 Mar; 80(3):139-47. PubMed ID: 3300097
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prostatic cancer. Transcortin levels during treatment with estramustine phosphate.
    Sandberg AA; Rosenthal H; Mittelman A; Murphy GP
    Urology; 1975 Jul; 6(1):17-21. PubMed ID: 1145919
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rectal palpation and transrectal fine needle aspiration of the prostate in the monitoring of prostate cancer: a study of 59 patients during treatment with estramustine phosphate or estrogens.
    Hedlund PO; Das D; Löwhagen T; Esposti P
    Prostate; 1989; 15(4):327-33. PubMed ID: 2594583
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomised, double-blind study of estramustine phosphate and leuprolide acetate.
    De la Grange AB
    Prog Clin Biol Res; 1987; 243B():227-8. PubMed ID: 3116555
    [No Abstract]   [Full Text] [Related]  

  • 51. [Treatment of advanced carcinoma of the prostate with Estracyt (author's transl)].
    Nagel R; Kölln CP
    Med Klin; 1976 Oct; 71(41):1724-8. PubMed ID: 824540
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Blood coagulation studies in patients with advanced carcinoma of the prostate treated with 2,6-cis-diphenylhexamethylcyclotetrasiloxane or estramustine-17-phosphate.
    Blombäck M; Edsmyr F; Kockum C; Paul C
    Urol Res; 1978; 6(2):95-102. PubMed ID: 664137
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Experiences with estramustinphosphate (Estracyt) in estrogen-resistant metastasizing prostatic cancer].
    Köller A; Lunglmayr G
    Wien Med Wochenschr; 1983; 133(7):179-81. PubMed ID: 6868629
    [No Abstract]   [Full Text] [Related]  

  • 54. The oestrogenic effects of ethinyl oestradiol/polyoestradiol phosphate and estramustine phosphate in patients with prostatic carcinoma. A comparative study of oestrogen sensitive liver proteins, gonadotrophins and prolactin.
    Daehlin L; Damber JE; von Schoultz B; Bergman B
    Br J Urol; 1986 Aug; 58(4):412-6. PubMed ID: 3092893
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients.
    Karr JP; Wajsman Z; Kirdani RY; Murphy GP; Sandberg AA
    J Urol; 1980 Aug; 124(2):232-6. PubMed ID: 7190620
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mode of action of estramustine phosphate in hormone dependent and hormone non-dependent prostate cancer.
    Hedlund PO
    Prog Clin Biol Res; 1985; 185A():197-202. PubMed ID: 3898129
    [No Abstract]   [Full Text] [Related]  

  • 57. Chemotherapy of prostatic cancer.
    Schmidt JD
    Urol Clin North Am; 1975 Feb; 2(1):185-96. PubMed ID: 1093059
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Estracyt treatment in prostatic neoplasms].
    Sander S
    Tidsskr Nor Laegeforen; 1976 Jan; 96(1):27-8. PubMed ID: 1257949
    [No Abstract]   [Full Text] [Related]  

  • 59. Oral estramustine phosphate. Prolonged therapy for advanced carcinoma of prostate.
    Catane R; Mittelman A; Kaufman J; Murphy GP
    N Y State J Med; 1976 Nov; 76(12):1978-81. PubMed ID: 1069190
    [No Abstract]   [Full Text] [Related]  

  • 60. Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancer.
    Boccardo F; Decensi A; Guarneri D; Martorana G; Giberti C; Giuliani L
    Cancer Chemother Pharmacol; 1988; 22(2):172-4. PubMed ID: 3409448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.